German Diabetes Stakeholders Like The New Talk On Strategy And Reimbursement, But Where's The Action?
Executive Summary
The up-to-10 million diabetics in Germany could benefit from a more optimal combination of digital tools and conventional case to maintain glucose control, say local IVD companies. But the industry is still waiting on the promised National Diabetes Strategy, while the government talks about more reimbursement support for innovation.
You may also be interested in...
Healthtech Responds To Providers’ Productivity, Workflow And Sustainability Concerns
Healthtech innovators are being asked by users and clinicians how technology solutions can increase health system efficiency and respond to concerns over staff shortages. Royal Philips’ Bert van Meurs fielded these questions at ECR 2024.
Healthtech Responds To Providers’ Productivity, Workflow And Sustainability Concerns
Healthtech innovators are being asked by users and clinicians how technology solutions can increase health system efficiency and respond to concerns over staff shortages. Royal Philips’ Bert van Meurs fielded these questions at ECR 2024.
Unfair Bias In Device Design: UK MHRA And Government Promise Action
A 15-month UK independent review of ethnic and other biases in device design has called for treatment inequity to be addressed at the highest levels of government, more resources for the MHRA and equity assessments to be included in approvals and post market surveillance.